Compass Therapeutics (CMPX) Stock Forecast: StockMap's 2-Week Call
CMPX stock forecast: StockMap's model makes no two-week call on Compass Therapeutics after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 3 of 4 two-week windows on CMPX since Sep 23; by chance, a call on the same dates was right 56% of the time.
Compass Therapeutics last closed at $0.68, +11.48% on the session.
Against the IVW growth benchmark the position is +13.81% over the forecast window.
Compass Therapeutics' market cap is $122.67M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).
Where CMPX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
23 daily calls for CMPX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Compass Therapeutics in the 20th percentile on return on equity, where 100 is best.
Compass Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Compass Therapeutics as the 264th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Compass Therapeutics ranks 143rd of 394 in the group, against a group median of -0.27.